Tumorigenic conversion of endothelial cells

Tumors of endothelial origin develop rarely. Until now, only two angiosarcoma (AS)-derived endothelial cell lines have been be isolated, ISO-HAS and AS-M. Both AS-derived endothelial cell lines presented the typical endothelial characteristics, such as the expression of CD31 and von Willebrand facto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental and molecular pathology 2003-10, Vol.75 (2), p.154-159
Hauptverfasser: Krump-Konvalinkova, Vera, Kleideiter, Elke, Friedrich, Ulrike, Klotz, Ulrich, Kirkpatrick, C.James
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumors of endothelial origin develop rarely. Until now, only two angiosarcoma (AS)-derived endothelial cell lines have been be isolated, ISO-HAS and AS-M. Both AS-derived endothelial cell lines presented the typical endothelial characteristics, such as the expression of CD31 and von Willebrand factor, but differed from normal endothelial cells in a nuclear expression of p53, in a delayed angiogenic reaction, and a reduced expression of caveolin. In addition, differences in the expression of cytokines and cell adhesion molecules responsive to proinflammatory stimuli were observed. While AS-M showed an expression pattern similar to that of human umbilical vein endothelial cells (HUVEC), ISO-HAS clearly differed from primary endothelial cells by a constitutive expression of E-selection, granulocyte macrophage colony-stimulating factor, and vascular endothelial cell adhesion molecule-1. Even though the telomeres of both AS-derived established cell lines were longer than telomeres of freshly isolated HUVEC, neither transcripts encoding telomerase nor telomerase activity were detected, suggesting that the tumor cells of endothelial origin may use a telomerase-independent mechanism for maintaining the telomere length. This observation has implications for development of therapeutic approaches for angiosarcoma.
ISSN:0014-4800
1096-0945
DOI:10.1016/S0014-4800(03)00074-1